Direct comparison
FBS Alternatives for Cell Culture Compared
Compare FBS alternatives -- serum-free, chemically defined, platelet lysate, and synthetic -- on documentation, cost, and regulatory fit for procurement.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about FBS Alternatives for Cell Culture Compared
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Serum-Free Media (SFM), Chemically Defined / Xeno-Free Media, Human Platelet Lysate (hPL), Synthetic Serum Replacement (SSR) compare side by side?
The table below compares Serum-Free Media (SFM), Chemically Defined / Xeno-Free Media, Human Platelet Lysate (hPL), Synthetic Serum Replacement (SSR) across 9 procurement-relevant dimensions, from what it is through best fit for.
Side-by-side comparison
| Dimension | Serum-Free Media (SFM) | Chemically Defined / Xeno-Free Media | Human Platelet Lysate (hPL) | Synthetic Serum Replacement (SSR) |
|---|---|---|---|---|
| What it is | Basal medium plus defined additives (recombinant growth factors, transferrin, insulin, lipids) replacing whole serum; may still include some purified animal- or human-derived proteins unless separately certified xeno-free. | A fully defined formulation where every component’s identity and concentration is known and controlled; typically animal-component-free (ACF), built on recombinant proteins. | Made by lysing pooled or single-donor human platelet concentrates to release stored growth factors (PDGF, TGF-β, VEGF, EGF, IGF-1); human-origin rather than chemically defined. | A manufactured formulation designed to functionally substitute for whole serum in specific applications (e.g., pluripotent stem cell culture) without using animal serum. |
| Animal-origin content | Serum-free, but not necessarily animal-component-free -- check the spec sheet for non-recombinant animal-derived proteins. | None, when certified animal-component-free/xeno-free; confirm via certification, not the “chemically defined” label alone. | Human-origin, not animal-origin -- removes bovine xenogeneic exposure but adds human-donor traceability and infectious-disease testing requirements. | Typically formulated animal-component-free or with recombinant substitutes; “synthetic” is a marketing term, not a regulatory one -- verify per product. |
| Typical application | General-purpose replacement across many adherent and suspension lines; common in biopharma production and standard research culture. | Regulatory-facing biomanufacturing, process development, and assay standardization requiring full compositional control. | Human primary and stem cell culture, particularly MSC expansion for research and cell-therapy manufacturing. | Pluripotent stem cell (ESC/iPSC) culture and other applications where serum-derived proteins are specifically undesirable. |
| Lot-to-lot consistency | Higher than FBS, but can still vary if any component is a purified biological rather than recombinant protein. | Highest of the group by design -- every component is specified and controlled. | Varies by donor pool; pooled-donor hPL reduces (but does not eliminate) variability versus single-donor hPL. | Generally high and manufacturer-controlled, but proprietary formulations limit independent verification of composition. |
| Cell-line adaptation burden | Moderate -- many established lines adapt without extensive re-optimization; sensitive/primary lines may need a step-down protocol. | Highest -- switching an FBS-adapted line usually requires a documented adaptation and qualification protocol. | Low to moderate for the human cell types it targets; fibrinogen carryover can require depletion or handling changes downstream. | Product- and cell-type-specific; check the manufacturer’s application data before committing a production process to it. |
| GMP/clinical-grade availability | Widely available at GMP grade from major suppliers. | Widely available at GMP grade; often the default for late-stage or commercial biomanufacturing. | Available at GMP grade from a smaller number of specialized suppliers -- confirm donor-screening and pooling documentation is part of the dossier. | Available at GMP grade for specific applications (e.g., stem cell banking); narrower availability than SFM/CDM. |
| Key documentation to request | CoA, animal-origin disclosure, endotoxin and mycoplasma testing results. | CoA with full formulation disclosure, ACF/xeno-free certification, recombinant-source documentation per protein. | Donor screening and infectious-disease testing records, pooling method and pool size, fibrinogen-depletion method (if applicable), CoA. | CoA, animal-component disclosure, application/validation data for the intended cell type, regulatory support file if used in a GMP process. |
| Relative cost vs FBS | Typically higher per liter than standard-grade FBS, partly offset by improved reproducibility and less lot-qualification labor. | Highest per-liter cost of the group, justified in regulatory-facing processes by consistency and lower re-validation risk. | Varies with donor-pool sourcing and grade; positioned as a premium human-origin option for cell-therapy work rather than a low-cost swap. | Premium-priced relative to FBS; weighed against a specific technical requirement rather than general cost savings. |
| Best fit for | Labs reducing serum lot variability and animal-serum dependency without a full defined-media validation project. | Regulatory-facing biomanufacturing and any process requiring full compositional traceability. | Human cell and cell-therapy work where a human-origin supplement is specifically preferred or required. | Stem cell programs needing an animal-component-free, application-validated serum substitute. |
Common questions
Common questions about Serum-Free Media (SFM) vs Chemically Defined / Xeno-Free Media vs Human Platelet Lysate (hPL) vs Synthetic Serum Replacement (SSR)
Is there a true drop-in replacement for FBS?
+
No. Every alternative requires at least some cell-line-specific adaptation and re-validation before it can substitute for FBS in an existing protocol -- from minor (serum-free media on a robust, established line) to substantial (a full defined-media qualification for a regulatory-facing process).
What does "synthetic FBS" actually mean?
+
It is not a formal regulatory or scientific category -- it is marketing shorthand, usually for a chemically defined or synthetic serum replacement designed to functionally substitute for whole serum (for example, in pluripotent stem cell culture) without containing any serum itself. Request the actual composition and animal-origin disclosure rather than relying on the term alone.
Do FBS alternatives eliminate animal-derived components entirely?
+
Only if specifically certified animal-component-free (ACF) or xeno-free. "Serum-free" only means no whole serum was added -- the medium can still contain animal-derived purified proteins unless the supplier separately certifies it ACF.
Are FBS alternatives required for regulatory compliance?
+
Not universally, but ancillary-material sourcing and traceability expectations for cell and gene therapy manufacturing -- reflected in standards such as ISO 20399 and USP General Chapter <1043> on ancillary materials -- push many clinical-grade and cell-therapy processes toward defined or human-origin alternatives because they are easier to document and qualify than an undefined animal-derived serum.
